세계의 반려동물 알레르기 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2031년)

Pet Allergy Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

US $ 4,995 ￦ 7,227,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,555,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 12,291,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

이 보고서는 세계 반려동물 알레르기 치료 시장에 대해 조사 분석했으며, 시장 성장 촉진요인, 동향, 기회, 과제 등 주요 시장 역학에 대한 상세한 분석을 통해 시장 전망에 대한 심층적인 통찰력을 제공합니다.

주요 인사이트

• 반려동물 알레르기 치료 시장 규모(2024년) : 26억 7,120만 달러
• 예상 시장 규모(2031년) : 39억 3,076만 달러
• 세계 시장 성장률(2024-2031년 CAGR) : 5.7%.

반려동물 알레르기 치료제 시장 - 조사 범위

반려동물 알레르기는 반려동물과 보호자 모두에게 전 세계적으로 심각한 건강 문제입니다. 반려동물 알레르기 치료 시장에는 고양이, 개 등 반려동물이 유발하는 알레르기 반응을 관리하기 위한 다양한 치료 옵션이 포함되어 있습니다. 이러한 치료에는 약물 치료, 면역 요법, 알레르겐 회피 전략, 새로운 생물학적 요법 등이 포함됩니다. 이 시장은 동물병원, 병원, 펫 케어 센터, 재택 케어 시설 등을 대상으로 하며, 효과적인 알레르기 관리 솔루션에 대한 반려동물 보호자들 수요 증가에 부응하고 있습니다.

시장 성장 촉진요인

세계 반려동물 알레르기 치료 시장은 반려동물 사육 증가, 반려동물 알레르기에 대한 인식 증가, 수의학 발전 등 여러 요인에 의해 주도되고 있습니다. 반려동물 소유주와 반려동물 사이에 알레르기 질환이 널리 퍼지면서 효과적인 치료 옵션에 대한 필요성이 증가하고 있습니다. 진단 도구와 치료 방법의 혁신은 진단 정확도와 치료 효과를 향상시켜 시장 성장을 더욱 촉진할 것입니다. 또한, 반려동물 보험의 보장 범위 확대와 반려동물 의료 인프라에 대한 투자도 시장 확대에 기여하고 있습니다.

시장 성장 억제요인

성장 가능성이 높은 반려동물 알레르기 치료제 시장은 규제 준수, 치료 결과의 편차, 보호자의 처방 치료 순응도 등의 문제에 직면해 있습니다. 동물용 의약품 및 생물학적 제제를 관리하는 규제 프레임워크는 제조업체와 의료 서비스 제공업체에게 규제 준수에 대한 부담을 가중시켜 시장 역학 및 경영 전략에 영향을 미치고 있습니다. 또한, 일부 지역에서는 선진 치료의 높은 비용과 제한적인 보험 적용 범위로 인해 시장 침투에 어려움을 겪고 있으며, 특히 신흥국에서는 시장 침투에 장애가 되고 있습니다.

시장 기회 :

인구통계학적 추세, 반려동물의 인간화, 반려동물 헬스케어 제품 및 서비스에 대한 소비자의 선호도 변화로 인해 반려동물 알레르기 치료 시장은 큰 성장 기회를 맞이하고 있습니다. 원격 의료와 디지털 건강 솔루션의 통합은 원격 진료를 용이하게 하고 반려동물 보호자의 수의학에 대한 접근성을 향상시킬 수 있습니다. 또한, 동물용 제약사, 반려동물사료 제조업체, 알레르기 전문의 협력은 치료 프로토콜과 알레르겐 관리 전략의 혁신을 촉진할 수 있습니다. 새로운 시장 기회를 활용하기 위해서는 반려동물 보호자와 수의사 전문가를 대상으로 한 교육 이니셔티브와 함께 R&D에 대한 전략적 투자가 필수적입니다.

본 보고서에서 다룬 주요 질문들

• 세계 반려동물 알레르기 치료 시장의 성장을 가속하는 요인은 무엇인가?
• 반려동물 보호자와 수의사들 사이에서 어떤 치료법과 진단 도구가 지지를 받고 있는가?
• 기술의 발전은 반려동물 알레르기 치료 시장 경쟁 구도를 어떻게 바꾸고 있는가?
• 반려동물 알레르기 치료 시장에 기여하는 주요 업체는 누구이며, 시장 리더십을 유지하기 위해 어떤 전략을 채택하고 있는가?
• 세계 반려동물 알레르기 치료 시장의 새로운 트렌드와 미래 전망은?

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위/분류
• 시장의 정의/범위/제한
• 포함과 제외

제3장 주요 시장 동향

• 시장에 영향을 미치는 주요 동향
• 제품 혁신/개발 동향

제4장 부가가치 통찰

• 제품 채택 분석
• 브랜드별 제품 USP/기능 분석
• 국가별 규제 상황
• 최근 제품 승인/발매
• 질병 역학
• Porter의 Five Forces 분석
• PESTLE 분석
• 밸류체인 분석
• 미충족 요구

제5장 시장 배경

• 거시경제 요인
• 예측 요인 - 관련성과 영향
• 시장 역학

제6장 세계 시장 수요(금액 또는 규모, 100만 달러) 분석

• 과거 시장 매출(100만 달러) 분석, 2019-2023년
• 현재 및 향후 시장 규모(100만 달러) 예측, 2024-2031년
  • 전년대비 성장 동향 분석
  • 절대적 달러 기회 분석
• 매출 기회 시나리오 - 가능성이 높은/유지보수 목표/낙관적

제7장 세계 시장 분석 : 약제 클래스별

• 서론/주요 조사 결과
• 과거 시장 규모(100만 달러) 분석, 약제 클래스별, 2019-2023년
• 현재 및 향후 시장 규모(100만 달러) 분석이라고 예측, 약제 클래스별, 2024-2031년
  • 항히스타민약
  • 부신피질 스테로이드
  • 면역치료
  • 항생제
• 시장 매력 분석 : 약제 클래스별

제8장 세계 시장 분석 : 적응증별

• 서론/주요 조사 결과
• 과거 시장 규모(100만 달러) 분석, 적응증별, 2019-2023년
• 현재 및 향후 시장 규모(100만 달러) 분석이라고 예측, 적응증별, 2024-2031년
  • 알레르기성 피부염
  • 음식 알레르기
  • 진드기 및 알레르기
  • 접촉 알레르기
• 시장 매력 분석 : 적응증별

제9장 세계 시장 분석 : 펫 유형별

• 서론/주요 조사 결과
• 과거 시장 규모(100만 달러) 분석, 반려동물 유형별, 2019-2023년
• 현재 및 향후 시장 규모(100만 달러) 분석이라고 예측, 반려동물 유형별, 2024-2031년
  • 견
  • 묘
  • 치류·토끼
• 시장 매력 분석 : 펫 유형별

제10장 세계 시장 분석 : 투여 경로별

• 서론/주요 조사 결과
• 과거 시장 규모(100만 달러) 분석, 투여 경로별, 2019-2023년
• 현재 및 향후 시장 규모(100만 달러) 분석이라고 예측, 투여 경로별, 2024-2031년
  • 경구제
  • 주사제
  • 국소
• 시장 매력 분석 : 투여 경로별

제11장 세계 시장 분석 : 유통 채널별

• 서론/주요 조사 결과
• 과거 시장 규모(100만 달러) 분석, 유통 채널별, 2019-2023년
• 현재 및 향후 시장 규모(100만 달러) 분석이라고 예측, 유통 채널별, 2024-2031년
  • 동물 병원
  • 소매 약국
  • 온라인 약국
  • 기타
• 시장 매력 분석 : 유통 채널별

제12장 세계 시장 분석 : 지역별

• 서론/주요 조사 결과
• 과거 시장 규모(100만 달러) 분석, 지역별, 2019-2023년
• 현재 및 향후 시장 규모(100만 달러) 분석이라고 예측, 지역별, 2024-2031년
  • 북미
  • 라틴아메리카
  • 유럽
  • 남아시아
  • 동아시아
  • 오세아니아
  • 중동 및 아프리카
• 시장 매력 분석 : 지역별

제13장 북미 시장 분석

제14장 라틴아메리카 시장 분석

제15장 유럽 시장 분석

제16장 동아시아 시장 분석

제17장 남아시아 시장 분석

제18장 오세아니아 시장 분석

제19장 중동 및 아프리카 시장 분석

제20장 시장 구조 분석

• 시장 분석 : 기업 Tier별
• 주요 기업의 시장 점유율 분석(%)
• 시장 입지 분석

제21장 경쟁 분석

• 경쟁 대시보드
• 주요 개발 분석
• 주요 기업의 브랜딩 및 프로모션 전략
• 경쟁 상세
  • Zoetis Animal Healthcare
  • Merck and Co.Inc.(US)
  • Boehringer Ingelheim GmbH
  • Elanco Animal Health Incorporated
  • Bayer AG
  • Vetoquinol SA
  • Dechra Pharmaceuticals PLC
  • Virbac SA
  • IDEXX Laboratories, Inc.
  • Ceva Sante Animale
  • Kindred Biosciences, Inc.
  • Phirbo Animal Health
  • Norbrook Laboratories Limited
  • Vetiquinol SA
  • Neogen Corporation
  • PetIQ, Inc.
  • Huvepharma AD
  • Chanelle Pharma Group Limited
  • Kepro
  • Biogenesis Bago

제22장 사용된 전제조건과 두자어

제23장 조사 방법

LSH

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the global Pet Allergy Treatment Market. The report provides an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges, offering detailed insights into the market landscape.

Key Insights:

• Pet Allergy Treatment Market Size (2024E): USD 2,671.20 million
• Projected Market Value (2031F): USD 3,930.76 million
• Global Market Growth Rate (CAGR 2024 to 2031):5.7%

Pet Allergy Treatment Market - Report Scope:

Pet allergies represent a significant health concern for both pets and their owners globally. The market for pet allergy treatment encompasses a range of therapeutic options aimed at managing allergic reactions caused by pets, such as cats and dogs. These treatments include medications, immunotherapy, allergen avoidance strategies, and emerging biologic therapies. The market caters to veterinary clinics, hospitals, pet care centers, and homecare settings, addressing a growing demand from pet owners seeking effective allergy management solutions.

Market Growth Drivers:

The global pet allergy treatment market is driven by several factors, including increasing pet ownership, rising awareness about pet allergies, and advancements in veterinary medicine. The growing prevalence of allergic conditions among pet owners and pets alike underscores the need for effective treatment options. Technological innovations in diagnostic tools and treatment modalities further enhance market growth, improving diagnostic accuracy and treatment efficacy. Moreover, the expanding pet insurance coverage and investments in pet healthcare infrastructure contribute to market expansion.

Market Restraints:

Despite promising growth prospects, the pet allergy treatment market faces challenges related to regulatory compliance, variability in treatment outcomes, and pet owner adherence to prescribed therapies. Regulatory frameworks governing veterinary pharmaceuticals and biologics impose compliance burdens on manufacturers and healthcare providers, influencing market dynamics and operational strategies. Additionally, the high cost of advanced treatments and limited reimbursement coverage in some regions hinder market penetration, particularly in emerging economies.

Market Opportunities:

The pet allergy treatment market presents significant growth opportunities driven by demographic trends, increasing pet humanization, and evolving consumer preferences for pet healthcare products and services. The integration of telemedicine and digital health solutions facilitates remote consultations and enhances pet owner access to veterinary care. Furthermore, collaborations between veterinary pharmaceutical companies, pet food manufacturers, and allergy specialists foster innovation in treatment protocols and allergen management strategies. Strategic investments in research and development, along with educational initiatives targeting pet owners and veterinary professionals, are essential to capitalize on emerging market opportunities.

Key Questions Answered in the Report:

• What factors are driving the growth of the pet allergy treatment market globally?
• Which treatment modalities and diagnostic tools are gaining traction among pet owners and veterinary professionals?
• How are technological advancements reshaping the competitive landscape of the pet allergy treatment market?
• Who are the key players contributing to the pet allergy treatment market, and what strategies are they employing to maintain market leadership?
• What are the emerging trends and future prospects in the global pet allergy treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global pet allergy treatment market, including pharmaceutical companies, veterinary clinics, and biotechnology firms, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop novel therapies, diagnostic tests, and allergen management solutions, catering to diverse pet owner preferences and clinical needs. Collaborations with pet healthcare providers, regulatory agencies, and pet insurance companies facilitate market access and promote technology adoption. Moreover, emphasis on evidence-based practice, veterinary education, and pet owner engagement enhances treatment outcomes and supports sustainable market growth in the evolving landscape of pet allergy management.

Key Companies Profiled:

• Zoetis Animal Healthcare
• Merck and Co Inc.
• Boehringer Ingelheim GmbH
• Elanco Animal Health Incorporated
• Bayer AG
• Vetoquinol S.A.
• Dechra Pharmaceuticals PLC
• Virbac SA
• IDEXX Laboratories, Inc.
• Ceva Sante Animale
• Kindred Biosciences, Inc.
• Phirbo Animal Health
• Norbrook Laboratories Limited
• Vetiquinol SA
• Neogen Corporation
• PetIQ, Inc.
• Huvepharma AD

Key Segments of Pet Allergy Treatment Industry Research

By Drug Class:

• Antihistamines
• Corticosteroids
• Immunotherapy
• Antibiotics

By Indication:

• Allergic Dermatitis
• Food Allergy
• Fleabite Allergy
• Contact Allergy

By Pet Type:

• Dogs
• Cats
• Rodents & Rabbits

By Route of Administration:

• Oral
• Injectable
• Topical

By Distribution Channel:

• Veterinary Hospitals
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand-side Trends
• 1.3. Supply-side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Value Added Insights

• 4.1. Product Adoption Analysis
• 4.2. Product USPs/Features Analysis, By Brands
• 4.3. Regulatory Landscape, By Country
• 4.4. Recent Product Approval/Launches
• 4.5. Disease Epidemiology
• 4.6. Porter's Analysis
• 4.7. PESTLE Analysis
• 4.8. Value Chain Analysis
• 4.9. Unmet Needs

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global Healthcare Expenditure Outlook
  • 5.1.2. Global Pharmaceutical Market Outlook
  • 5.1.3. Global Animal Healthcare Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Rising Rate of Pet Adoption
  • 5.2.2. Increase in Research and Development
  • 5.2.3. Strategic Collaborations among players
  • 5.2.4. Cost of Product
  • 5.2.5. Business Expansions
  • 5.2.6. Frequency of Product Approval
  • 5.2.7. Pet Care Insurance
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. Global Market Demand (in Value or Size in US$ Million) Analysis 2019-2023 and Forecast, 2024-2031

• 6.1. Historical Market Value (US$ Million) Analysis, 2019-2023
• 6.2. Current and Future Market Size (US$ Million) Projections, 2024-2031
  • 6.2.1. Y-o-Y Growth Trend Analysis
  • 6.2.2. Absolute $ Opportunity Analysis
• 6.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic

7. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Drug Class

• 7.1. Introduction / Key Findings
• 7.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2019-2023
• 7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2024-2031
  • 7.3.1. Antihistamines
  • 7.3.2. Corticosteroids
  • 7.3.3. Immunotherapy
  • 7.3.4. Antibiotics
• 7.4. Market Attractiveness Analysis By Drug Class

8. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Indication

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Million) Analysis By Indication, 2019-2023
• 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2024-2031
  • 8.3.1. Allergic Dermatitis
  • 8.3.2. Food Allergy
  • 8.3.3. Fleabite Allergy
  • 8.3.4. Contact Allergy
• 8.4. Market Attractiveness Analysis By Indication

9. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Pet Type

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Million) Analysis By Pet Type, 2019-2023
• 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Pet Type, 2024-2031
  • 9.3.1. Dogs
  • 9.3.2. Cats
  • 9.3.3. Rodents and rabbits
• 9.4. Market Attractiveness Analysis By Pet Type

10. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Route of Administration

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2019-2023
• 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2024-2031
  • 10.3.1. Oral
  • 10.3.2. Injectable
  • 10.3.3. Topical
• 10.4. Market Attractiveness Analysis By Route of Administration

11. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2019-2023
• 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2024-2031
  • 11.3.1. Veterinary Hospitals
  • 11.3.2. Retail Pharmacies
  • 11.3.3. Online Pharmacies
  • 11.3.4. Others
• 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2019-2023 and Forecast 2024-2031, by Region

• 12.1. Introduction / Key Findings
• 12.2. Historical Market Size (US$ Million) Analysis By Region, 2019-2023
• 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2024-2031
  • 12.3.1. North America
  • 12.3.2. Latin America
  • 12.3.3. Europe
  • 12.3.4. South Asia
  • 12.3.5. East Asia
  • 12.3.6. Oceania
  • 12.3.7. Middle East and Africa
• 12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2019-2023 and Forecast 2024-2031

• 13.1. Introduction / Key Findings
• 13.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 13.3.1. By Country
    • 13.3.1.1. United States
    • 13.3.1.2. Canada
  • 13.3.2. By Drug Class
  • 13.3.3. By Indication
  • 13.3.4. By Pet Type
  • 13.3.5. By Route of Administration
  • 13.3.6. By Distribution Channel
• 13.4. Market Attractiveness Analysis By Region
  • 13.4.1. By Country
  • 13.4.2. By Drug Class
  • 13.4.3. By Indication
  • 13.4.4. By Pet Type
  • 13.4.5. By Route of Administration
  • 13.4.6. By Distribution Channel
• 13.5. Market trends
• 13.6. Key Market Participants - Intensity Mapping
• 13.7. Drivers and Restraints - Impact Analysis
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. United States Market Analysis
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.1.2.1. By Drug Class
      • 13.8.1.2.2. By Indication
      • 13.8.1.2.3. By Pet Type
      • 13.8.1.2.4. By Route of Administration
      • 13.8.1.2.5. By Distribution Channel
  • 13.8.2. Canada Market Analysis
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.2.2.1. By Drug Class
      • 13.8.2.2.2. By Indication
      • 13.8.2.2.3. By Pet Type
      • 13.8.2.2.4. By Route of Administration
      • 13.8.2.2.5. By Distribution Channel

14. Latin America Market Analysis 2019-2023 and Forecast 2024-2031

• 14.1. Introduction / Key Findings
• 14.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 14.3.1. By Country
    • 14.3.1.1. Brazil
    • 14.3.1.2. Mexico
    • 14.3.1.3. Argentina
    • 14.3.1.4. Rest of Latin America
  • 14.3.2. By Drug Class
  • 14.3.3. By Indication
  • 14.3.4. By Pet Type
  • 14.3.5. By Route of Administration
  • 14.3.6. By Distribution Channel
• 14.4. Market Attractiveness Analysis By Region
  • 14.4.1. By Country
  • 14.4.2. By Drug Class
  • 14.4.3. By Indication
  • 14.4.4. By Pet Type
  • 14.4.5. By Route of Administration
  • 14.4.6. By Distribution Channel
• 14.5. Market trends
• 14.6. Key Market Participants - Intensity Mapping
• 14.7. Drivers and Restraints - Impact Analysis
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. Brazil Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.1.2.1. By Drug Class
      • 14.8.1.2.2. By Indication
      • 14.8.1.2.3. By Pet Type
      • 14.8.1.2.4. By Route of Administration
      • 14.8.1.2.5. By Distribution Channel
  • 14.8.2. Mexico Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.2.2.1. By Drug Class
      • 14.8.2.2.2. By Indication
      • 14.8.2.2.3. By Pet Type
      • 14.8.2.2.4. By Route of Administration
      • 14.8.2.2.5. By Distribution Channel
  • 14.8.3. Argentina Market Analysis
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.3.2.1. By Drug Class
      • 14.8.3.2.2. By Indication
      • 14.8.3.2.3. By Pet Type
      • 14.8.3.2.4. By Route of Administration
      • 14.8.3.2.5. By Distribution Channel

15. Europe Market Analysis 2019-2023 and Forecast 2024-2031

• 15.1. Introduction / Key Findings
• 15.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 15.3.1. By Country
    • 15.3.1.1. Germany
    • 15.3.1.2. France
    • 15.3.1.3. Spain
    • 15.3.1.4. Russia
    • 15.3.1.5. Italy
    • 15.3.1.6. BENELUX
    • 15.3.1.7. United Kingdom
    • 15.3.1.8. Rest of Europe
  • 15.3.2. By Drug Class
  • 15.3.3. By Indication
  • 15.3.4. By Pet Type
  • 15.3.5. By Route of Administration
  • 15.3.6. By Distribution Channel
• 15.4. Market Attractiveness Analysis By Region
  • 15.4.1. By Country
  • 15.4.2. By Drug Class
  • 15.4.3. By Indication
  • 15.4.4. By Pet Type
  • 15.4.5. By Route of Administration
  • 15.4.6. By Distribution Channel
• 15.5. Market trends
• 15.6. Key Market Participants - Intensity Mapping
• 15.7. Drivers and Restraints - Impact Analysis
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. Germany Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.1.2.1. By Drug Class
      • 15.8.1.2.2. By Indication
      • 15.8.1.2.3. By Pet Type
      • 15.8.1.2.4. By Route of Administration
      • 15.8.1.2.5. By Distribution Channel
  • 15.8.2. France Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.2.2.1. By Drug Class
      • 15.8.2.2.2. By Indication
      • 15.8.2.2.3. By Pet Type
      • 15.8.2.2.4. By Route of Administration
      • 15.8.2.2.5. By Distribution Channel
  • 15.8.3. Spain Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.3.2.1. By Drug Class
      • 15.8.3.2.2. By Indication
      • 15.8.3.2.3. By Pet Type
      • 15.8.3.2.4. By Route of Administration
      • 15.8.3.2.5. By Distribution Channel
  • 15.8.4. Russia Market Analysis
    • 15.8.4.1. Introduction
    • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.4.2.1. By Drug Class
      • 15.8.4.2.2. By Indication
      • 15.8.4.2.3. By Pet Type
      • 15.8.4.2.4. By Route of Administration
      • 15.8.4.2.5. By Distribution Channel
  • 15.8.5. Italy Market Analysis
    • 15.8.5.1. Introduction
    • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.5.2.1. By Drug Class
      • 15.8.5.2.2. By Indication
      • 15.8.5.2.3. By Pet Type
      • 15.8.5.2.4. By Route of Administration
      • 15.8.5.2.5. By Distribution Channel
  • 15.8.6. BENELUX Market Analysis
    • 15.8.6.1. Introduction
    • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.6.2.1. By Drug Class
      • 15.8.6.2.2. By Indication
      • 15.8.6.2.3. By Pet Type
      • 15.8.6.2.4. By Route of Administration
      • 15.8.6.2.5. By Distribution Channel
  • 15.8.7. United Kingdom Market Analysis
    • 15.8.7.1. Introduction
    • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.7.2.1. By Drug Class
      • 15.8.7.2.2. By Indication
      • 15.8.7.2.3. By Pet Type
      • 15.8.7.2.4. By Route of Administration
      • 15.8.7.2.5. By Distribution Channel

16. East Asia Market Analysis 2019-2023 and Forecast 2024-2031

• 16.1. Introduction / Key Findings
• 16.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 16.3.1. By Country
    • 16.3.1.1. China
    • 16.3.1.2. Japan
    • 16.3.1.3. South Korea
  • 16.3.2. By Drug Class
  • 16.3.3. By Indication
  • 16.3.4. By Pet Type
  • 16.3.5. By Route of Administration
  • 16.3.6. By Distribution Channel
• 16.4. Market Attractiveness Analysis By Region
  • 16.4.1. By Country
  • 16.4.2. By Drug Class
  • 16.4.3. By Indication
  • 16.4.4. By Pet Type
  • 16.4.5. By Route of Administration
  • 16.4.6. By Distribution Channel
• 16.5. Market trends
• 16.6. Key Market Participants - Intensity Mapping
• 16.7. Drivers and Restraints - Impact Analysis
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. China Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.1.2.1. By Drug Class
      • 16.8.1.2.2. By Indication
      • 16.8.1.2.3. By Pet Type
      • 16.8.1.2.4. By Route of Administration
      • 16.8.1.2.5. By Distribution Channel
  • 16.8.2. Japan Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.2.2.1. By Drug Class
      • 16.8.2.2.2. By Indication
      • 16.8.2.2.3. By Pet Type
      • 16.8.2.2.4. By Route of Administration
      • 16.8.2.2.5. By Distribution Channel
  • 16.8.3. South Korea Market Analysis
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.3.2.1. By Drug Class
      • 16.8.3.2.2. By Indication
      • 16.8.3.2.3. By Pet Type
      • 16.8.3.2.4. By Route of Administration
      • 16.8.3.2.5. By Distribution Channel

17. South Asia Market Analysis 2019-2023 and Forecast 2024-2031

• 17.1. Introduction / Key Findings
• 17.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 17.3.1. By Country
    • 17.3.1.1. India
    • 17.3.1.2. Indonesia
    • 17.3.1.3. Thailand
    • 17.3.1.4. Philippines
    • 17.3.1.5. Malaysia
    • 17.3.1.6. Vietnam
    • 17.3.1.7. Rest of South Asia
  • 17.3.2. By Drug Class
  • 17.3.3. By Indication
  • 17.3.4. By Pet Type
  • 17.3.5. By Route of Administration
  • 17.3.6. By Distribution Channel
• 17.4. Market Attractiveness Analysis By Region
  • 17.4.1. By Country
  • 17.4.2. By Drug Class
  • 17.4.3. By Indication
  • 17.4.4. By Pet Type
  • 17.4.5. By Route of Administration
  • 17.4.6. By Distribution Channel
• 17.5. Market trends
• 17.6. Key Market Participants - Intensity Mapping
• 17.7. Drivers and Restraints - Impact Analysis
• 17.8. Country Level Analysis & Forecast
  • 17.8.1. India Market Analysis
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.1.2.1. By Drug Class
      • 17.8.1.2.2. By Indication
      • 17.8.1.2.3. By Pet Type
      • 17.8.1.2.4. By Route of Administration
      • 17.8.1.2.5. By Distribution Channel
  • 17.8.2. Indonesia Market Analysis
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.2.2.1. By Drug Class
      • 17.8.2.2.2. By Indication
      • 17.8.2.2.3. By Pet Type
      • 17.8.2.2.4. By Route of Administration
      • 17.8.2.2.5. By Distribution Channel
  • 17.8.3. Thailand Market Analysis
    • 17.8.3.1. Introduction
    • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.3.2.1. By Drug Class
      • 17.8.3.2.2. By Indication
      • 17.8.3.2.3. By Pet Type
      • 17.8.3.2.4. By Route of Administration
      • 17.8.3.2.5. By Distribution Channel
  • 17.8.4. Philippines Market Analysis
    • 17.8.4.1. Introduction
    • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.4.2.1. By Drug Class
      • 17.8.4.2.2. By Indication
      • 17.8.4.2.3. By Pet Type
      • 17.8.4.2.4. By Route of Administration
      • 17.8.4.2.5. By Distribution Channel
  • 17.8.5. Malaysia Market Analysis
    • 17.8.5.1. Introduction
    • 17.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.5.2.1. By Drug Class
      • 17.8.5.2.2. By Indication
      • 17.8.5.2.3. By Pet Type
      • 17.8.5.2.4. By Route of Administration
      • 17.8.5.2.5. By Distribution Channel
  • 17.8.6. Vietnam Market Analysis
    • 17.8.6.1. Introduction
    • 17.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.6.2.1. By Drug Class
      • 17.8.6.2.2. By Indication
      • 17.8.6.2.3. By Pet Type
      • 17.8.6.2.4. By Route of Administration
      • 17.8.6.2.5. By Distribution Channel

18. Oceania Market Analysis 2019-2023 and Forecast 2024-2031

• 18.1. Introduction / Key Findings
• 18.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 18.3.1. By Country
    • 18.3.1.1. Australia
    • 18.3.1.2. New Zealand
  • 18.3.2. By Drug Class
  • 18.3.3. By Indication
  • 18.3.4. By Pet Type
  • 18.3.5. By Route of Administration
  • 18.3.6. By Distribution Channel
• 18.4. Market Attractiveness Analysis By Region
  • 18.4.1. By Country
  • 18.4.2. By Drug Class
  • 18.4.3. By Indication
  • 18.4.4. By Pet Type
  • 18.4.5. By Route of Administration
  • 18.4.6. By Distribution Channel
• 18.5. Market trends
• 18.6. Key Market Participants - Intensity Mapping
• 18.7. Drivers and Restraints - Impact Analysis
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. Australia Market Analysis
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.1.2.1. By Drug Class
      • 18.8.1.2.2. By Indication
      • 18.8.1.2.3. By Pet Type
      • 18.8.1.2.4. By Route of Administration
      • 18.8.1.2.5. By Distribution Channel
  • 18.8.2. New Zealand Market Analysis
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.2.2.1. By Drug Class
      • 18.8.2.2.2. By Indication
      • 18.8.2.2.3. By Pet Type
      • 18.8.2.2.4. By Route of Administration
      • 18.8.2.2.5. By Distribution Channel

19. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2031

• 19.1. Introduction / Key Findings
• 19.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
• 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
  • 19.3.1. By Country
    • 19.3.1.1. GCC Countries
    • 19.3.1.2. Turkey
    • 19.3.1.3. Egypt
    • 19.3.1.4. Israel
    • 19.3.1.5. South Africa
    • 19.3.1.6. Northern Africa
    • 19.3.1.7. Rest of Middle East and Africa
  • 19.3.2. By Drug Class
  • 19.3.3. By Indication
  • 19.3.4. By Pet Type
  • 19.3.5. By Route of Administration
  • 19.3.6. By Distribution Channel
• 19.4. Market Attractiveness Analysis By Region
  • 19.4.1. By Country
  • 19.4.2. By Drug Class
  • 19.4.3. By Indication
  • 19.4.4. By Pet Type
  • 19.4.5. By Route of Administration
  • 19.4.6. By Distribution Channel
• 19.5. Market trends
• 19.6. Key Market Participants - Intensity Mapping
• 19.7. Drivers and Restraints - Impact Analysis
• 19.8. Country Level Analysis & Forecast
  • 19.8.1. GCC Countries Market Analysis
    • 19.8.1.1. Introduction
    • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.1.2.1. By Drug Class
      • 19.8.1.2.2. By Indication
      • 19.8.1.2.3. By Pet Type
      • 19.8.1.2.4. By Route of Administration
      • 19.8.1.2.5. By Distribution Channel
  • 19.8.2. Turkey Market Analysis
    • 19.8.2.1. Introduction
    • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.2.2.1. By Drug Class
      • 19.8.2.2.2. By Indication
      • 19.8.2.2.3. By Pet Type
      • 19.8.2.2.4. By Route of Administration
      • 19.8.2.2.5. By Distribution Channel
  • 19.8.3. Egypt Market Analysis
    • 19.8.3.1. Introduction
    • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.3.2.1. By Drug Class
      • 19.8.3.2.2. By Indication
      • 19.8.3.2.3. By Pet Type
      • 19.8.3.2.4. By Route of Administration
      • 19.8.3.2.5. By Distribution Channel
  • 19.8.4. Israel Market Analysis
    • 19.8.4.1. Introduction
    • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.4.2.1. By Drug Class
      • 19.8.4.2.2. By Indication
      • 19.8.4.2.3. By Pet Type
      • 19.8.4.2.4. By Route of Administration
      • 19.8.4.2.5. By Distribution Channel
  • 19.8.5. South Africa Market Analysis
    • 19.8.5.1. Introduction
    • 19.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.5.2.1. By Drug Class
      • 19.8.5.2.2. By Indication
      • 19.8.5.2.3. By Pet Type
      • 19.8.5.2.4. By Route of Administration
      • 19.8.5.2.5. By Distribution Channel
  • 19.8.6. Northern Africa Market Analysis
    • 19.8.6.1. Introduction
    • 19.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.6.2.1. By Drug Class
      • 19.8.6.2.2. By Indication
      • 19.8.6.2.3. By Pet Type
      • 19.8.6.2.4. By Route of Administration
      • 19.8.6.2.5. By Distribution Channel

20. Market Structure Analysis

• 20.1. Market Analysis by Tier of Companies
• 20.2. Market Share Analysis of Top Players (%)
• 20.3. Market Presence Analysis
  • 20.3.1. Regional Footprint of Players
  • 20.3.2. Product Footprint of Players
  • 20.3.3. Channel Footprint of Players

21. Competition Analysis

• 21.1. Competition Dashboard
• 21.2. Key Development Analysis
• 21.3. Branding and Promotional Strategies, By Key Players
• 21.4. Competition Deep Dive
  • 21.4.1. Zoetis Animal Healthcare
    • 21.4.1.1. Overview
    • 21.4.1.2. Product Portfolio
    • 21.4.1.3. Key Financials
    • 21.4.1.4. Sales Footprint
    • 21.4.1.5. SWOT Analysis
    • 21.4.1.6. Strategy Overview
      • 21.4.1.6.1. Marketing Strategies
      • 21.4.1.6.2. Channel Strategies
      • 21.4.1.6.3. Product Strategies
  • 21.4.2. Merck and Co.Inc. (US)
    • 21.4.2.1. Overview
    • 21.4.2.2. Product Portfolio
    • 21.4.2.3. Key Financials
    • 21.4.2.4. Sales Footprint
    • 21.4.2.5. SWOT Analysis
    • 21.4.2.6. Strategy Overview
      • 21.4.2.6.1. Marketing Strategies
      • 21.4.2.6.2. Channel Strategies
      • 21.4.2.6.3. Product Strategies
  • 21.4.3. Boehringer Ingelheim GmbH
    • 21.4.3.1. Overview
    • 21.4.3.2. Product Portfolio
    • 21.4.3.3. Key Financials
    • 21.4.3.4. Sales Footprint
    • 21.4.3.5. SWOT Analysis
    • 21.4.3.6. Strategy Overview
      • 21.4.3.6.1. Marketing Strategies
      • 21.4.3.6.2. Channel Strategies
      • 21.4.3.6.3. Product Strategies
  • 21.4.4. Elanco Animal Health Incorporated
    • 21.4.4.1. Overview
    • 21.4.4.2. Product Portfolio
    • 21.4.4.3. Key Financials
    • 21.4.4.4. Sales Footprint
    • 21.4.4.5. SWOT Analysis
    • 21.4.4.6. Strategy Overview
      • 21.4.4.6.1. Marketing Strategies
      • 21.4.4.6.2. Channel Strategies
      • 21.4.4.6.3. Product Strategies
  • 21.4.5. Bayer AG
    • 21.4.5.1. Overview
    • 21.4.5.2. Product Portfolio
    • 21.4.5.3. Key Financials
    • 21.4.5.4. Sales Footprint
    • 21.4.5.5. SWOT Analysis
    • 21.4.5.6. Strategy Overview
      • 21.4.5.6.1. Marketing Strategies
      • 21.4.5.6.2. Channel Strategies
      • 21.4.5.6.3. Product Strategies
  • 21.4.6. Vetoquinol S.A.
    • 21.4.6.1. Overview
    • 21.4.6.2. Product Portfolio
    • 21.4.6.3. Key Financials
    • 21.4.6.4. Sales Footprint
    • 21.4.6.5. SWOT Analysis
    • 21.4.6.6. Strategy Overview
      • 21.4.6.6.1. Marketing Strategies
      • 21.4.6.6.2. Channel Strategies
      • 21.4.6.6.3. Product Strategies
  • 21.4.7. Dechra Pharmaceuticals PLC
    • 21.4.7.1. Overview
    • 21.4.7.2. Product Portfolio
    • 21.4.7.3. Key Financials
    • 21.4.7.4. Sales Footprint
    • 21.4.7.5. SWOT Analysis
    • 21.4.7.6. Strategy Overview
      • 21.4.7.6.1. Marketing Strategies
      • 21.4.7.6.2. Channel Strategies
      • 21.4.7.6.3. Product Strategies
  • 21.4.8. Virbac SA
    • 21.4.8.1. Overview
    • 21.4.8.2. Product Portfolio
    • 21.4.8.3. Key Financials
    • 21.4.8.4. Sales Footprint
    • 21.4.8.5. SWOT Analysis
    • 21.4.8.6. Strategy Overview
      • 21.4.8.6.1. Marketing Strategies
      • 21.4.8.6.2. Channel Strategies
      • 21.4.8.6.3. Product Strategies
  • 21.4.9. IDEXX Laboratories, Inc.
    • 21.4.9.1. Overview
    • 21.4.9.2. Product Portfolio
    • 21.4.9.3. Key Financials
    • 21.4.9.4. Sales Footprint
    • 21.4.9.5. SWOT Analysis
    • 21.4.9.6. Strategy Overview
      • 21.4.9.6.1. Marketing Strategies
      • 21.4.9.6.2. Channel Strategies
      • 21.4.9.6.3. Product Strategies
  • 21.4.10. Ceva Sante Animale
    • 21.4.10.1. Overview
    • 21.4.10.2. Product Portfolio
    • 21.4.10.3. Key Financials
    • 21.4.10.4. Sales Footprint
    • 21.4.10.5. SWOT Analysis
    • 21.4.10.6. Strategy Overview
      • 21.4.10.6.1. Marketing Strategies
      • 21.4.10.6.2. Channel Strategies
      • 21.4.10.6.3. Product Strategies
  • 21.4.11. Kindred Biosciences, Inc.
    • 21.4.11.1. Overview
    • 21.4.11.2. Product Portfolio
    • 21.4.11.3. Key Financials
    • 21.4.11.4. Sales Footprint
    • 21.4.11.5. SWOT Analysis
    • 21.4.11.6. Strategy Overview
      • 21.4.11.6.1. Marketing Strategies
      • 21.4.11.6.2. Channel Strategies
      • 21.4.11.6.3. Product Strategies
  • 21.4.12. Phirbo Animal Health
    • 21.4.12.1. Overview
    • 21.4.12.2. Product Portfolio
    • 21.4.12.3. Key Financials
    • 21.4.12.4. Sales Footprint
    • 21.4.12.5. SWOT Analysis
    • 21.4.12.6. Strategy Overview
      • 21.4.12.6.1. Marketing Strategies
      • 21.4.12.6.2. Channel Strategies
      • 21.4.12.6.3. Product Strategies
  • 21.4.13. Norbrook Laboratories Limited
    • 21.4.13.1. Overview
    • 21.4.13.2. Product Portfolio
    • 21.4.13.3. Key Financials
    • 21.4.13.4. Sales Footprint
    • 21.4.13.5. SWOT Analysis
    • 21.4.13.6. Strategy Overview
      • 21.4.13.6.1. Marketing Strategies
      • 21.4.13.6.2. Channel Strategies
      • 21.4.13.6.3. Product Strategies
  • 21.4.14. Vetiquinol SA
    • 21.4.14.1. Overview
    • 21.4.14.2. Product Portfolio
    • 21.4.14.3. Key Financials
    • 21.4.14.4. Sales Footprint
    • 21.4.14.5. SWOT Analysis
    • 21.4.14.6. Strategy Overview
      • 21.4.14.6.1. Marketing Strategies
      • 21.4.14.6.2. Channel Strategies
      • 21.4.14.6.3. Product Strategies
  • 21.4.15. Neogen Corporation
    • 21.4.15.1. Overview
    • 21.4.15.2. Product Portfolio
    • 21.4.15.3. Key Financials
    • 21.4.15.4. Sales Footprint
    • 21.4.15.5. SWOT Analysis
    • 21.4.15.6. Strategy Overview
      • 21.4.15.6.1. Marketing Strategies
      • 21.4.15.6.2. Channel Strategies
      • 21.4.15.6.3. Product Strategies
  • 21.4.16. PetIQ, Inc.
    • 21.4.16.1. Overview
    • 21.4.16.2. Product Portfolio
    • 21.4.16.3. Key Financials
    • 21.4.16.4. Sales Footprint
    • 21.4.16.5. SWOT Analysis
    • 21.4.16.6. Strategy Overview
      • 21.4.16.6.1. Marketing Strategies
      • 21.4.16.6.2. Channel Strategies
      • 21.4.16.6.3. Product Strategies
  • 21.4.17. Huvepharma AD
    • 21.4.17.1. Overview
    • 21.4.17.2. Product Portfolio
    • 21.4.17.3. Key Financials
    • 21.4.17.4. Sales Footprint
    • 21.4.17.5. SWOT Analysis
    • 21.4.17.6. Strategy Overview
      • 21.4.17.6.1. Marketing Strategies
      • 21.4.17.6.2. Channel Strategies
      • 21.4.17.6.3. Product Strategies
  • 21.4.18. Chanelle Pharma Group Limited
    • 21.4.18.1. Overview
    • 21.4.18.2. Product Portfolio
    • 21.4.18.3. Key Financials
    • 21.4.18.4. Sales Footprint
    • 21.4.18.5. SWOT Analysis
    • 21.4.18.6. Strategy Overview
      • 21.4.18.6.1. Marketing Strategies
      • 21.4.18.6.2. Channel Strategies
      • 21.4.18.6.3. Product Strategies
  • 21.4.19. Kepro
    • 21.4.19.1. Overview
    • 21.4.19.2. Product Portfolio
    • 21.4.19.3. Key Financials
    • 21.4.19.4. Sales Footprint
    • 21.4.19.5. SWOT Analysis
    • 21.4.19.6. Strategy Overview
      • 21.4.19.6.1. Marketing Strategies
      • 21.4.19.6.2. Channel Strategies
      • 21.4.19.6.3. Product Strategies
  • 21.4.20. Biogenesis Bago
    • 21.4.20.1. Overview
    • 21.4.20.2. Product Portfolio
    • 21.4.20.3. Key Financials
    • 21.4.20.4. Sales Footprint
    • 21.4.20.5. SWOT Analysis
    • 21.4.20.6. Strategy Overview
      • 21.4.20.6.1. Marketing Strategies
      • 21.4.20.6.2. Channel Strategies
      • 21.4.20.6.3. Product Strategies

22. Assumptions and Acronyms Used

23. Research Methodology

관련자료